Form: 8-K

Current report filing

January 24, 2013

Exhibit 99.1

 

LOGO

RESMED INC. ANNOUNCES RECORD FINANCIAL RESULTS FOR THE

QUARTER ENDED AND SIX MONTHS ENDED DECEMBER 31, 2012

SAN DIEGO, California, January 24, 2013 – ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended December 31, 2012. Revenue for the quarter ended December 31, 2012 was $376.5 million, a 13% increase (a 14% increase on a constant currency basis) over the quarter ended December 31, 2011. For the quarter ended December 31, 2012, net income was $77.9 million, an increase of 24% compared to the quarter ended December 31, 2011. Diluted earnings per share for the quarter ended December 31, 2012 were $0.53, an increase of 26% compared to the quarter ended December 31, 2011.

SG&A expenses were $107.8 million for the quarter ended December 31, 2012, an increase of 7% (an 8% increase on a constant currency basis) over the quarter ended December 31, 2011. The increase in SG&A was primarily due to expenses necessary to support sales growth. SG&A costs were 28.6% of revenue in the quarter ended December 31, 2012, compared to 30.2% in the quarter ended December 31, 2011.

R&D expenses were $30.3 million for the quarter ended December 31, 2012, or 8.1% of revenue. R&D expenses increased by 11% (also an 11% increase on a constant currency basis) compared to the quarter ended December 31, 2011.

The company amortized acquired intangibles of $2.5 million ($1.9 million, net of tax) during the quarter ended December 31, 2012. Stock-based compensation costs incurred during the quarter ended December 31, 2012 of $9.5 million ($6.5 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and our employee stock purchase plan.

For the six months ended December 31, 2012, revenue was $716.3 million, an increase of 11% over the six months ended December 31, 2011 (a 13% increase on a constant currency basis). For the six months ended December 31, 2012, net income was $149.2 million, an increase of 32% compared to the six months ended December 31, 2011. Diluted earnings per share for the six months ended December 31, 2012 were $1.02 per diluted share, an increase of 36% compared to the six months ended December 31, 2011.

Inventory, at $194.8 million, increased by $20.5 million compared to June 30, 2012. Accounts receivable days sales outstanding, at 68 days, remained unchanged compared with June 30, 2012.

Additionally, the Board of Directors has today declared a quarterly dividend of $0.17 per share, which will have a record date of February 19, 2013, and be payable on March 19, 2013. The dividend will be paid in U.S. currency to holders of ResMed’s common stock trading on the New York Stock Exchange (NYSE). Holders of Chess Depositary Instruments (CDIs) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. Because the two exchanges have different settlement and transfer procedures, the ex-dividend periods before the record date will be different for common stock and for CDIs. The ex-dividend date will be February 13, 2013 for CDI holders and February 15, 2013 for common stock holders. As a result of these differences, ResMed has requested a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from February 13, 2013 through February 19, 2013, inclusive.

Peter C. Farrell Ph.D, chairman and chief executive officer, commented, “In the second quarter of fiscal 2013 we showed strong year-over-year growth on both top and bottom lines. Revenue in the Americas increased by 16%, to $211.8 million over the prior year’s quarter. Revenue outside the Americas was $164.7 million, an increase of 10% over the prior year’s quarter. In constant currency terms, revenue outside the Americas increased by 12%. Operating profit for the December quarter was $92.1 million, cash flow from operations was $93.6 million, while gross margin was 61.8%, all demonstrating excellent operating performance. There was also a continuing shift to higher value flow generators, like S9 Autoset™ and S9 bilevels, and mask and accessory sales remained strong. During the quarter, we also repurchased 1.0 million shares, at a cost of $40.0 million, as part of our ongoing capital management program.

“We had a solid quarter across the board. And we believe we are in the early stages of an exciting market dynamic for sleep-disordered breathing (SDB), which we have been pioneering for many years, by offering full solutions to therapy providers and critical


information for the reimbursement community. In short, we don’t just provide high quality flow generators and a highly regarded range of comfortable, effective and preferred masks and accessories, we offer robust data solutions that drive compliance and adherence. This combination is a significant value proposition for home medical equipment providers, because these solutions drive efficiencies and create additional business opportunities. And by providing valuable clinical and economic data to payors, we strive to help them more fully appreciate SDB therapy’s positive effect on health and cost benefit outcomes. We believe that our continuing advocacy for screening, diagnosis, treatment, and monitoring patient adherence to SDB therapy presents a significant opportunity to improve health and quality of life, contain healthcare costs, and curtail the development of multiple co-morbidities, many of which are far more devastating and costly than SDB.”

About ResMed

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

ResMed will host a conference call at 1:30 p.m. U.S. Pacific Time today to discuss these quarterly results. Individuals wishing to access the conference call may do so via ResMed’s website at www.resmed.com or by dialing 847-585-4405 (domestic) or +1 847-585-4405 (international) and entering conference passcode no. 33995965. Please allow extra time prior to the call to visit the website and download the streaming media player (Windows Media Player) required to listen to the internet broadcast. The online archive of the broadcast will be available approximately 30 minutes after the live call and will be available for two weeks. A telephone replay of the conference call is available by dialing 630-652-3042 (domestic) and +1 630-652-3042 (international) and entering conference I.D. No. 33995965.

Further information can be obtained by contacting Constance Bienfait at ResMed Inc., San Diego, at (858) 836-5971; Brett Sandercock at ResMed Limited, Sydney, at (+612) 8884-2090; or by visiting the Company’s multilingual website at www.resmed.com.

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company’s future revenue, earnings or expenses, new product development and new markets for the Company’s products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company’s Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company’s website.

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited)

(In US$ thousands, except per share data)

 

    

Three Months Ended

December 31,

    

Six Months Ended

December 31,

 
     2012     2011      2012     2011  

Net revenue

   $ 376,537      $ 332,738       $ 716,269      $ 647,513   

Cost of sales

     143,825        134,023         274,909        263,743   
  

 

 

   

 

 

    

 

 

   

 

 

 

Gross profit

     232,712        198,715         441,360        383,770   
  

 

 

   

 

 

    

 

 

   

 

 

 

Operating expenses:

         

Selling, general and administrative

     107,815        100,552         206,118        194,755   

Research and development

     30,326        27,218         57,546        53,424   

Amortization of acquired intangible assets

     2,501        3,691         5,138        7,462   
  

 

 

   

 

 

    

 

 

   

 

 

 

Total operating expenses

     140,642        131,461         268,802        255,641   
  

 

 

   

 

 

    

 

 

   

 

 

 

Income from operations

     92,070        67,254         172,558        128,129   
  

 

 

   

 

 

    

 

 

   

 

 

 

Other income (expenses), net:

         

Interest income (expense), net

     8,498        7,181         16,970        14,103   

Other, net

     (2,168     8,496         (227     7,196   
  

 

 

   

 

 

    

 

 

   

 

 

 

Total other income (expenses), net

     6,330        15,677         16,743        21,299   
  

 

 

   

 

 

    

 

 

   

 

 

 

Income before income taxes

     98,400        82,931         189,301        149,428   

Income taxes

     20,458        20,059         40,094        36,038   
  

 

 

   

 

 

    

 

 

   

 

 

 

Net income

   $ 77,942      $ 62,872       $ 149,207      $ 113,390   
  

 

 

   

 

 

    

 

 

   

 

 

 

Basic earnings per share

   $ 0.54      $ 0.43       $ 1.04      $ 0.76   

Diluted earnings per share

   $ 0.53      $ 0.42       $ 1.02      $ 0.75   

Basic shares outstanding

     143,214        146,369         142,931        148,368   

Diluted shares outstanding

     146,689        149,515         146,382        151,835   

 

- More -


RESMED INC AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited - In US$ thousands)

 

     December 31,
2012
    June 30,
2012
 

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 958,280      $ 809,541   

Accounts receivable, net

     281,439        283,160   

Inventories

     194,804        174,351   

Prepayments, deferred income taxes and other current assets

     95,328        94,099   
  

 

 

   

 

 

 

Total current assets

     1,529,851        1,361,151   
  

 

 

   

 

 

 

Property, plant and equipment, net

     439,575        434,363   

Goodwill

     279,384        256,209   

Other intangibles

     58,198        54,827   

Deferred income taxes and other non-current assets

     23,367        31,319   
  

 

 

   

 

 

 

Total non-current assets

     800,524        776,718   
  

 

 

   

 

 

 

Total assets

   $ 2,330,375      $ 2,137,869   
  

 

 

   

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

    

Current liabilities:

    

Accounts payable

     52,119        55,006   

Accrued expenses

     135,372        127,381   

Deferred revenue

     43,784        41,563   

Income taxes payable

     18,955        27,777   

Deferred income taxes

     784        1,073   

Current portion of long-term debt

     54        52   
  

 

 

   

 

 

 

Total current liabilities

     251,068        252,852   
  

 

 

   

 

 

 

Non-current liabilities:

    

Deferred income taxes

     9,373        8,843   

Deferred revenue

     14,055        14,384   

Income taxes payable

     3,569        3,380   

Non-current portion of long-term debt

     300,798        250,783   
  

 

 

   

 

 

 

Total non-current liabilities

     327,795        277,390   
  

 

 

   

 

 

 

Total liabilities

     578,863        530,242   
  

 

 

   

 

 

 

Stockholders’ Equity:

    

Common stock

     574        568   

Additional paid-in capital

     960,109        899,717   

Retained earnings

     1,467,230        1,366,712   

Treasury stock

     (943,877     (895,826

Accumulated other comprehensive income

     267,476        236,456   
  

 

 

   

 

 

 

Total stockholders’ equity

     1,751,512        1,607,627   
  

 

 

   

 

 

 

Total liabilities and stockholders’ equity

   $ 2,330,375      $ 2,137,869   
  

 

 

   

 

 

 

 

- End -